BRPI0409364A - processo para tratamento da doença de parkinson - Google Patents

processo para tratamento da doença de parkinson

Info

Publication number
BRPI0409364A
BRPI0409364A BRPI0409364-0A BRPI0409364A BRPI0409364A BR PI0409364 A BRPI0409364 A BR PI0409364A BR PI0409364 A BRPI0409364 A BR PI0409364A BR PI0409364 A BRPI0409364 A BR PI0409364A
Authority
BR
Brazil
Prior art keywords
parkinson
disease
safinamide
treatment process
disease treatment
Prior art date
Application number
BRPI0409364-0A
Other languages
English (en)
Inventor
Fariello Ruggero
Carlo Cattaneo
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of BRPI0409364A publication Critical patent/BRPI0409364A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSOS PARA TRATAMENTO DA DOENçA DE PARKINSON". A presente invenção refere-se aos usos da safinamida, de derivados da safinamida e de inibidores do MAO-B em novos tipos de tratamento para a Doença de Parkinson. Mais especificamente, a invenção se refere a processos para o tratamento da Doença de Parkinson através da administração da safinamida, de um derivado da safinamida ou de um inibidor da MAO-B, em combinação com outros agentes ou tratamentos para a Doença de Parkinson, tal como a levodopa/PDI ou os agonistas da dopamina.
BRPI0409364-0A 2003-04-11 2004-04-08 processo para tratamento da doença de parkinson BRPI0409364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
BRPI0409364A true BRPI0409364A (pt) 2006-04-25

Family

ID=33159845

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409364-0A BRPI0409364A (pt) 2003-04-11 2004-04-08 processo para tratamento da doença de parkinson

Country Status (28)

Country Link
US (3) US8283380B2 (pt)
EP (2) EP1613296B1 (pt)
JP (2) JP2006522800A (pt)
KR (2) KR101129015B1 (pt)
CN (2) CN102274517B (pt)
AR (1) AR044007A1 (pt)
AT (1) ATE435012T1 (pt)
AU (1) AU2004228782B2 (pt)
BR (1) BRPI0409364A (pt)
CA (1) CA2523188C (pt)
CY (3) CY1109295T1 (pt)
DE (1) DE602004021790D1 (pt)
DK (2) DK1613296T3 (pt)
ES (2) ES2454272T3 (pt)
FR (1) FR15C0054I2 (pt)
HU (1) HUS1500043I1 (pt)
IL (2) IL171331A (pt)
LU (1) LU92782I2 (pt)
MX (1) MXPA05010873A (pt)
NL (1) NL300752I2 (pt)
NO (3) NO334316B1 (pt)
NZ (1) NZ542910A (pt)
PL (2) PL1613296T3 (pt)
PT (2) PT2070526E (pt)
RU (1) RU2342929C2 (pt)
SI (2) SI2070526T1 (pt)
TW (1) TWI340640B (pt)
WO (1) WO2004089353A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
ATE317280T1 (de) * 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
PL1658062T3 (pl) * 2003-08-25 2010-07-30 Newron Pharm Spa Pochodne alfa-aminoamidu jako środki przeciwzapalne
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CN101018546B (zh) * 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US8772346B2 (en) 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
CA2653012C (en) 2006-06-19 2014-08-05 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino) propan amides
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
PT2155663T (pt) 2007-06-15 2018-01-16 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida substituídos e sua utilização como moduladores dos canais de sódio e/ou de cálcio
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
CN101896456B (zh) 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
CA2707646C (en) * 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
EP2285769B1 (en) 2008-06-02 2014-08-13 Generics [UK] Limited A process for the preparation of enantiomerically pure amines
AU2009254929B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited An improved process for the preparation of amines
DK2303330T4 (da) * 2008-06-06 2021-09-13 Pharma Two B Ltd Farmaceutiske sammensætninger til behandling af parkinsons sygdom
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
HUE030504T2 (en) 2010-04-27 2017-05-29 Newron Pharm Spa Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
CA2845854A1 (en) 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
BR112016024502A8 (pt) * 2014-04-21 2021-06-29 Civitas Therapeutics Inc uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento
EP3202759B1 (en) * 2014-10-02 2019-12-18 Megabiowood Co., Ltd. Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
LT3341380T (lt) * 2015-08-27 2020-01-10 Prexton Therapeutics Sa Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) * 2017-01-14 2018-07-19 Mischley Laurie Kathern Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
CA3072994A1 (en) * 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
EA202091127A1 (ru) 2017-11-02 2020-09-22 Замбон С.П.А. Фармацевтические композиции, включающие сафинамид
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
US20230028539A1 (en) * 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院(石河子市技工学校) 一种葡萄酒洗浸奶酪加工方法
US20230181508A1 (en) * 2020-08-31 2023-06-15 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
EP0828513B1 (en) * 1995-05-26 2004-01-21 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
DK1613296T3 (da) 2009-10-05
AU2004228782A1 (en) 2004-10-21
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
ES2326373T3 (es) 2009-10-08
LU92782I2 (fr) 2015-09-22
NO2015018I2 (no) 2015-07-23
EP2070526A1 (en) 2009-06-17
ATE435012T1 (de) 2009-07-15
PL2070526T3 (pl) 2014-08-29
NO2015018I1 (no) 2015-08-03
DK2070526T3 (da) 2014-03-24
NZ542910A (en) 2007-10-26
NO20054640D0 (no) 2005-10-10
US8283380B2 (en) 2012-10-09
TWI340640B (en) 2011-04-21
ES2454272T3 (es) 2014-04-10
AU2004228782B2 (en) 2010-05-20
HUS1500043I1 (hu) 2018-11-28
PL1613296T3 (pl) 2009-12-31
CN1771030A (zh) 2006-05-10
NO335537B1 (no) 2014-12-22
RU2005131422A (ru) 2006-04-27
US20150150833A1 (en) 2015-06-04
CA2523188A1 (en) 2004-10-21
TW200505423A (en) 2005-02-16
AR044007A1 (es) 2005-08-24
KR101129015B1 (ko) 2012-04-20
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
RU2342929C2 (ru) 2009-01-10
PT2070526E (pt) 2014-03-31
WO2004089353A8 (en) 2005-09-01
MXPA05010873A (es) 2006-03-21
SI1613296T1 (sl) 2009-10-31
EP1613296A2 (en) 2006-01-11
SI2070526T1 (sl) 2014-05-30
CY2015025I1 (el) 2016-04-13
CN102274517A (zh) 2011-12-14
CY1109295T1 (el) 2014-07-02
FR15C0054I1 (fr) 2015-11-09
US20130053368A1 (en) 2013-02-28
CY2015025I2 (el) 2016-04-13
IL216403A (en) 2015-01-29
NO20131417L (no) 2005-12-09
NL300752I2 (pt) 2016-07-05
JP2006522800A (ja) 2006-10-05
WO2004089353A3 (en) 2004-12-16
FR15C0054I2 (fr) 2018-01-26
EP1613296B1 (en) 2009-07-01
JP2013067647A (ja) 2013-04-18
CA2523188C (en) 2012-09-25
KR20060010745A (ko) 2006-02-02
IL171331A (en) 2012-03-29
US9492410B2 (en) 2016-11-15
KR20110070929A (ko) 2011-06-24
NO334316B1 (no) 2014-02-03
PT1613296E (pt) 2009-07-30
CN102274517B (zh) 2018-08-31
US8901176B2 (en) 2014-12-02
EP2070526B1 (en) 2014-02-26
IL216403A0 (en) 2011-12-29
WO2004089353A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
BRPI0409364A (pt) processo para tratamento da doença de parkinson
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BR0208373A (pt) Inibidores da tirosina cinase
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
BRPI0617165B1 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI1008727B8 (pt) derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
BRPI0518846A2 (pt) composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung
DK1656122T3 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
TW200420549A (en) Thiazole derivatives
HK1141231A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
BR112012006010A2 (pt) composto de glicina
MX2007012794A (es) Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
BRPI0509540A (pt) uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
BRPI0411898A (pt) método para deposição uniforme de ativos para tratamento de tecidos em um sistema não-aquoso para tratamento de tecidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: NEWRON PHARMACEUTICALS S.P.A. (IT)